SLC7A11 As a Gateway of Metabolic Perturbation and Ferroptosis Vulnerability in Cancer

Overview

Journal Antioxidants (Basel)

Date 2022 Dec 23

PMID 36552652

Authors

Jaewang Lee

Jong-Lyel Roh

Affiliations

Soon will be listed here.

Abstract

SLC7A11 is a cell transmembrane protein composing the light chain of system xc, transporting extracellular cystine into cells for cysteine production and GSH biosynthesis. SLC7A11 is a critical gateway for redox homeostasis by maintaining the cellular levels of GSH that counter cellular oxidative stress and suppress ferroptosis. SLC7A11 is overexpressed in various human cancers and regulates tumor development, proliferation, metastasis, microenvironment, and treatment resistance. Upregulation of SLC7A11 in cancers is needed to adapt to high oxidative stress microenvironments and maintain cellular redox homeostasis. High basal ROS levels and SLC7A11 dependences in cancer cells render them vulnerable to further oxidative stress. Therefore, cyst(e)ine depletion may be an effective new strategy for cancer treatment. However, the effectiveness of the SLC7A11 inhibitors or cyst(e)inase has been established in many preclinical studies but has not reached the stage of clinical trials for cancer patients. A better understanding of cysteine and SLC7A11 functions regulating and interacting with redox-active proteins and their substrates could be a promising strategy for cancer treatment. Therefore, this review intends to understand the role of cysteine in antioxidant and redox signaling, the regulators of cysteine bioavailability in cancer, the role of SLC7A11 linking cysteine redox signaling in cancer metabolism and targeting SLC7A11 for novel cancer therapeutics.

Citing Articles

Integrative Disulfidptosis-Based Risk Assessment for Prognostic Stratification and Immune Profiling in Glioma.

Niu X, Li G, Kahlert U, Ding L, Zheng J, Li C J Cell Mol Med. 2025; 29(4):e70429.

PMID: 39993959 PMC: 11850091. DOI: 10.1111/jcmm.70429.

Ferroptosis in Pulmonary Disease and Lung Cancer: Molecular Mechanisms, Crosstalk Regulation, and Therapeutic Strategies.

Guo D, Cai S, Deng L, Xu W, Fu S, Lin Y MedComm (2020). 2025; 6(3):e70116.

PMID: 39991627 PMC: 11847630. DOI: 10.1002/mco2.70116.

Deciphering Epigenetic and Post-Translational Modifications in Ferroptosis: A Scientometric and Visualization Study.

Cao S, Wei Y, Yue Y, Wang D, Xiong A, Zeng H Int J Med Sci. 2025; 22(3):508-527.

PMID: 39898258 PMC: 11783085. DOI: 10.7150/ijms.104222.

High glucose induces podocyte ferroptosis through BAP1/SLC7A11 pathway.

Peiyao R, Xueli M, Wenbo S, Danna Z, Jianguang G, Juan J Heliyon. 2025; 11(1):e40590.

PMID: 39816499 PMC: 11732670. DOI: 10.1016/j.heliyon.2024.e40590.

Sodium aescinate-induced hepatotoxicity via ATF4/GSH/GPX4 axis-mediated ferroptosis.

Xi C, Zhou J, Zheng X, Fu X, Xie M Sci Rep. 2025; 15(1):1141.

PMID: 39774712 PMC: 11706965. DOI: 10.1038/s41598-024-79723-2.

References

Lim J, Delaidelli A, Minaker S, Zhang H, Colovic M, Yang H . Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc Natl Acad Sci U S A. 2019; 116(19):9433-9442. PMC: 6511045. DOI: 10.1073/pnas.1821323116. View

Stockwell B, Friedmann Angeli J, Bayir H, Bush A, Conrad M, Dixon S . Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017; 171(2):273-285. PMC: 5685180. DOI: 10.1016/j.cell.2017.09.021. View

Sato M, Onuma K, Domon M, Hasegawa S, Suzuki A, Kusumi R . Loss of the cystine/glutamate antiporter in melanoma abrogates tumor metastasis and markedly increases survival rates of mice. Int J Cancer. 2020; 147(11):3224-3235. DOI: 10.1002/ijc.33262. View

Yang Y, Yee D . IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC-. Cancer Res. 2014; 74(8):2295-305. PMC: 4006361. DOI: 10.1158/0008-5472.CAN-13-1803. View

Long Y, Tao H, Karachi A, Grippin A, Jin L, Chang Y . Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma. Cancer Res. 2019; 80(3):499-509. DOI: 10.1158/0008-5472.CAN-19-1577. View

Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y . Redox imbalance in cystine/glutamate transporter-deficient mice. J Biol Chem. 2005; 280(45):37423-9. DOI: 10.1074/jbc.M506439200. View

Schafer F, Buettner G . Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med. 2001; 30(11):1191-212. DOI: 10.1016/s0891-5849(01)00480-4. View

Huang Y, Dai Z, Barbacioru C, Sadee W . Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 2005; 65(16):7446-54. DOI: 10.1158/0008-5472.CAN-04-4267. View

Sharma M, Seidlitz E, Singh G . Cancer cells release glutamate via the cystine/glutamate antiporter. Biochem Biophys Res Commun. 2009; 391(1):91-5. DOI: 10.1016/j.bbrc.2009.10.168. View

10.

Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P . BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. 2018; 20(10):1181-1192. PMC: 6170713. DOI: 10.1038/s41556-018-0178-0. View

11.

Pompella A, Visvikis A, Paolicchi A, De Tata V, Casini A . The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol. 2003; 66(8):1499-503. DOI: 10.1016/s0006-2952(03)00504-5. View

12.

Sugano K, Maeda K, Ohtani H, Nagahara H, Shibutani M, Hirakawa K . Expression of xCT as a predictor of disease recurrence in patients with colorectal cancer. Anticancer Res. 2015; 35(2):677-82. View

13.

Romero R, Sayin V, Davidson S, Bauer M, Singh S, LeBoeuf S . Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med. 2017; 23(11):1362-1368. PMC: 5677540. DOI: 10.1038/nm.4407. View

14.

Koppula P, Zhang Y, Shi J, Li W, Gan B . The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate. J Biol Chem. 2017; 292(34):14240-14249. PMC: 5572906. DOI: 10.1074/jbc.M117.798405. View

15.

Borges C, Sherma N . Techniques for the analysis of cysteine sulfhydryls and oxidative protein folding. Antioxid Redox Signal. 2014; 21(3):511-31. PMC: 4076987. DOI: 10.1089/ars.2013.5559. View

16.

Roh J, Kim E, Jang H, Shin D . Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition. Free Radic Biol Med. 2017; 104:1-9. DOI: 10.1016/j.freeradbiomed.2017.01.002. View

17.

Liu J, Xia X, Huang P . xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling. Mol Ther. 2020; 28(11):2358-2366. PMC: 7647670. DOI: 10.1016/j.ymthe.2020.08.021. View

18.

Ge C, Cao B, Feng D, Zhou F, Zhang J, Yang N . The down-regulation of SLC7A11 enhances ROS induced P-gp over-expression and drug resistance in MCF-7 breast cancer cells. Sci Rep. 2017; 7(1):3791. PMC: 5476638. DOI: 10.1038/s41598-017-03881-9. View

19.

Rojo de la Vega M, Chapman E, Zhang D . NRF2 and the Hallmarks of Cancer. Cancer Cell. 2018; 34(1):21-43. PMC: 6039250. DOI: 10.1016/j.ccell.2018.03.022. View

20.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View